GLSI Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Greenwich Lifesciences Inc (GLSI) does not present a strong buy opportunity for a beginner investor with a long-term strategy at this time. While the company shows some positive developments in its clinical trials and financial improvement, the lack of significant trading signals, neutral trading sentiment, and uncertain short-term stock trend do not justify immediate investment.
The technical indicators show a bullish trend with MACD positively expanding and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). RSI is neutral at 65.42, and the stock is trading near its resistance level (R1: 27.437). However, the stock's next-day and next-week probabilities suggest minor declines, while the next-month projection shows a modest gain of 2.63%.
The FLAMINGO-01 trial has shown promising preliminary data with a 70-80% reduction in recurrence rates in the non-HLA-A*02 arm.
The trial is expanding globally to 150 clinical sites, targeting 500 HLA-A*02 patients, which indicates growth potential.
Financial improvement in Q3 2025 with a 55.57% YoY increase in net income and a 50% YoY improvement in EPS.
The company has no significant revenue generation (revenue remains at $0).
The stock's short-term trend indicates potential minor declines in the next day and week.
Trading sentiment from hedge funds and insiders is neutral, with no significant activity.
In Q3 2025, Greenwich Lifesciences reported no revenue growth (revenue remains $0), but net income improved to -$4,151,845, up 55.57% YoY. EPS also improved to -0.3, up 50% YoY, reflecting better cost management despite no revenue generation.
No analyst rating or price target changes are available for GLSI.
